Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction

European Journal of Heart Failure

Volumn 4, Issue 6, 2002, Pages 713-718

  Youn, Tae jin ^a   Piao, Hainan ^a   Kwon, Jin sook ^a   Choi, So young ^a   Kim, Hyung sam ^a   Park, Daegyun ^b   Kim, Dong woon ^a   Kim, Young gyu ^a   Cho, Myeong chan ^a  

^a Chungbuk National University College of Medicine   (South Korea)

^b Hallym University   (South Korea)

Author keywords

Calcineurin; Heart failure; Hypertrophy; Infarction; Remodeling

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ECHOCARDIOGRAPHY; FEMALE; HEART DILATATION; HEART INFARCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEMODYNAMICS; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CALCINEURIN; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ENZYME INHIBITORS; HEART FUNCTION TESTS; HEMODYNAMIC PROCESSES; HYPERTROPHY, LEFT VENTRICULAR; MALE; MYOCARDIAL INFARCTION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; REFERENCE VALUES; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 0036895666     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00120-4     Document Type: Article

References (36)

1. Meizlish JL, Berger HJ, Plankey M, Errico D, Levy W, Zaret BL. Functional left ventricular aneurysm formation after acute anterior transmural myocardial infarction: Incidence, natural history, and prognostic implications. N Engl J Med 1984;311:1001-6.
2. Weisman HF, Bush DE, Mannisi JA, Bulkley BH. Global cardiac remodeling after acute myocardial infarction: A study in the rat model. J Am Coll Cardiol 1985;5:1355-62.
3. Hammermeister KE, DeRouen TA, Dodge HT. Variables predictive of survival in patients with coronary disease. Selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic, and quantitative angiographic evaluations. Circulation 1979;59:421-30.
4. Picard MH, Wilkins GT, Ray PA, Weyman AE. Natural history of left ventricular size and function after acute myocardial infarction. Assessment and prediction by echocardiographic endocardial surface mapping. Circulation 1990;82:484-94.
5. McKay RG, Pfeffer MA, Pasternak RC, et al. Left ventricular remodeling after myocardial infarction: A corollary to infarct expansion. Circulation 1986;74:693-702.
6. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990;81:1161-72.
7. Eichhorn E, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: A new era in the treatment of heart failure. Circulation 1996;94:2285-96.
8. Wagoner LE, Walsh RA. The cellular pathophysiology of progression to heart failure. Curr Opin Cardiol 1996;11:237-44.
9. Sussman MA, Lim HW, Gude N, et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:1690-3.
10. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-28.
11. Sugden PH. Signaling in myocardial hypertrophy: Life after calcineurin? Circ Res 1999;84:633-46.
12. Olson EN, Molkentin JD. Prevention of cardiac hypertrophy by calcineurin inhibition: Hope or hype? Circ Res 1999;84:623-32.
13. Force T, Rosenzweig A, Choukroun G, Hajjar R. Calcineurin inhibitors and cardiac hypertrophy. Lancet 1999;353:1290-2.
14. Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000;105:1395-406.
15. Passier R, Zeng H, Frey N, et al. CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest 2000;105:1395-406. [15] Shimoyama M, Hayashi D, Takimoto E, et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999;100:2449-54.
16. Lim HW, De Windt LJ, Steinberg L, et al. Calcineurin expression, activation, and function in cardiac pressure-overload hypertrophy. Circulation 2000;101:2431-7.
17. Shimoyama M, Hayashi D, Zou Y, et al. Calcineurin inhibitor attenuates the development and induces the regression of cardiac hypertrophy in rats with salt-sensitive hypertension. Circulation 2000;102:1996-2004.
18. Sakata Y, Masuyama T, Yamamoto K, et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 2000;102:2269-75.
19. Ruwhof C, van der Laarse A. Mechanical stress-induced cardiac hypertrophy: Mechanisms and signal transduction pathways. Cardiovasc Res 2000;47:23-37.
20. Zhang W, Kowal RC, Rusnak F, Sikkink RA, Olson EN, Victor RG. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res 1999;84:722-8.
21. Ding B, Price RL, Borg TK, Weinberg EO, Halloran PF, Lorell BH. Pressure overload induces severe hypertrophy in mice treated with cyclosporine, an inhibitor of calcineurin. Circ Res 1999;84:729-34.
22. Youn TJ, Kim HS, Oh BH. Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: Effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade. Basic Res Cardiol 1999;94:246-53.
23. Massoudy P, Zahler S, Kupatt C, Reder E, Becker BF, Gerlach E. Cardioprotection by cyclosporine A in experimental ischemia and reperfusion - Evidence for a nitric oxide-dependent mechanism mediated by endothelin. J Mol Cell Cardiol 1997;29:535-44.
24. Weinbrenner C, Liu GS, Downey JM, Cohen MV. Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. Cardiovasc Res 1998;38:678-84.
25. Cai Q, Baxter GF, Yellon DM. Reduction of infarct size in isolated rat heart by CsA and FK 506: Possible role of phosphatase inhibition. Cardiovasc Drugs Ther 1998;12:499-501.
26. Kajstura J, Cheng W, Reiss K, et al. Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest 1996;74:86-107.
27. Oie E, Bjornerheim R, Clausen OP, Attramadal H. Cyclosporin A inhibits cardiac hypertrophy and enhances cardiac dysfunction during postinfarction failure in rats. Am J Physiol Heart Circ Physiol 2000;278:H2115-H2123.
28. Ghali JK, Liao Y, Simmons B, Castaner A, Cao G, Cooper RS. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Inter Med 1992;117:831-6.
29. Sullivan JM, Vander Zwaag RV, el-Zeky F, Ramanathan KB, Mirvis DM. Left ventricular hypertrophy: Effect on survival. J Am Coll Cardiol 1993;22:508-13.
30. Quinones MA, Greenberg BH, Kopelen HA, et al. Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: Significance of left ventricular hypertrophy. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 2000;35:1237-44.
31. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991;83:1849-65.
32. Volders PGA, Illems IEMG, Cleutjens JPM, Arends JW, Havenith MG, Daemen MJAP. Interstitial collagen is increased in the non-infarcted human myocardium after myocardial infarction. J Mol Cell Cardiol 1993;25:1317-23.
33. Merx W, Yoon MS, Han J. The role of local disparity on conduction and recovery on ventricular vulnerability to fibrillation. Am Heart J 1977;94:603-10.
34. Francis GS, McDonald KM. Left ventricular hypertrophy: An initial response to myocardial injury. Am J Cardiol 1992;69:3G-7G.
35. Meguro T, Hong C, Asai K, et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ Res 1999;84:735-40.
36. Lim HW, De Windt LJ, Mante J, et al. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol 2000;32:697-709.